A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Trial Profile

A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AVANTI
  • Most Recent Events

    • 09 Dec 2017 Results (n=2056) presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 11 Oct 2016 Results (n=2135) of a pooled analysis from ML21165, AVANTI and AVAREG studies assessing real-world effectiveness and safety in clinically important subgroups, presented at the 41st European Society for Medical Oncology Congress.
    • 12 Dec 2015 Status changed from active, no longer recruiting to recruiting, as per results presented at the 38th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top